Jeremy
Hello, I'm Jeremy Levy, consultant nephrologist at Imperial NHS Trust.
Andrew
And I'm Andrew Frankel, a colleague of Jeremy's and also a consultant nephrologist at Imperial College Healthcare NHS Trust. And welcome to another episode in our series of podcasts for kidney's sake. Now we've actually talked about potassium quite a lot across this podcast series. Only recently did we cover hyperkalemia risk when we discussed Finerenone.
It also particularly comes up every time we talk about optimising ACE inhibitors or angiotensin receptor blockers. Today though, we want to focus specifically on the treatment for high potassium itself and in particular the potassium binders. We're doing this because NICE have just made a significant change to how one of these agents is recommended for use.
And we believe that this is going to have a significant but beneficial impact on primary care in patients.
Jeremy
Yeah, I completely agree, Andrew. We have been talking a lot about potassium, but this does feel like a really good moment to dedicate a whole episode to the potassium binders. But I think looking at that advice, it's not really just sort of an incremental tweak. And even though not all our audience is in England, but it's a really important change to how potassium binders can be used, to who's eligible, how to start these drugs. And that advice is important for anybody, particularly in primary care.
So think what you and I want to achieve by the end of this podcast is that our audience, particularly in primary care, of course knows when to reach for these new potassium binders, how to start the medicine, and therefore can feel much more confident about prescribing them. They are relatively new drugs and everybody always has some barriers to new medications, but we really shouldn't be any more treating these. New potassium binders as something only to be started and used by secondary care. They really should be part of the armamentarium of primary care clinicians shouldn't they?
Andrew
They should generally and I'm gonna though challenge you fairly early on in the podcast. The idea that they're relatively new, of course you and I have been using these for six years. Primary care have been using them on secondary care's advice for many years. And I tend not to use the term new potassium binders because they're six years old. They're already walking, running, talking and going to school.
Jeremy
You're quite right, you're quite right, they're not babies.
Andrew
So let's start with what's actually changed. NICE has published final guidance called a technology appraisal. For those who are interested in this, it's TA1148, which relates to the use of sodium, zirconium, cyclosilicate, or Lochelma. And of course, now in England, all of our integrated care boards have 90 days to implement these changes. The very simple key change that they've made.
Which on the face of it seems quite marginal, is that they've lowered the potassium threshold for starting low calma from six down to five point five. That might sound like a small adjustment, but Kidney Research UK together with AstraZeneca both estimate it roughly doubles the number of patients in England and Wales who now qualify for potassium binders. Because there's a large group of people sitting there persistently in that five point five to six range who previously were just monitored and given dietary advice.
Jeremy
And you're right Andrew, it looks like it's trivial but actually that's a really really big shift in the people who we could use potassium binders in. And for us it's really important in chronic kidney disease because it's that group where we're really trying to optimise and get people on maximum doses of renin angiotensin blockade with ACE inhibitors and angiotensin blockers. Because the potassium is often what limits that. So that's what we're going to talk about because it...
It's where the problem potentially lies. And in a way, we discussed that last time with finerenone, where high potassiums might limit your use of a drug that's really protective for stopping or slowing down progression of chronic kidney disease.
Andrew
I should highlight Jeremy that the current change is specific to lokelma and there is of course another potassium binder Patiromer and patiromer's technology appraisal has not been reviewed and its threshold is unchanged. It still requires a confirmed potassium of six or above. But I anticipate for common sense reasons that there should be or there will be similar change for Patiromer
As it just doesn't make sense to have two different thresholds for each. So, Jeremy, let's move on and make a start by considering what does this actually mean for how primary care will manage patients day to day?
Jeremy
Right, okay, so previously these drugs had to be started in secondary care, the patient had to be seen and initiated in a secondary care or hospital clinic and then primary care would take over the prescribing. But under this new guidance, Lokelma particularly, can now be initiated directly in primary care as long as you've had some advice from secondary care. That doesn't have to be a formal outpatient review, it can be advice from a nephrologist, a cardiologist or actually any clinician, geriatrician.
Managing the emergency or an acute medical unit. It's very often these patients have been seen in an acute medical unit. And critically, that advice might be electronic, like might be by email, might be telephone, it doesn't have to be a face to face appointment. So it's advice from somebody in secondary care that these, Lokelma can be used. lots of you are having virtual consultations. So it's advice from secondary care, but doesn't have to be seeing the patient face to face. And then the thresholds change.
from 6 millimoles per litre down to 5.5 millimoles per litre. And that sounds like it's going to be a lot more work for primary care. But actually it isn't because these are patients who bounce backwards and forwards between primary and secondary care. And that in itself often means more work, more checking of potassium. So actually overall, this will allow less interventions to manage potassium in these people. And it will reduce the number of people with high blood potassium being called back to primary care.
Andrew
Yeah, I think that's a really important point to mention and there's good data out there to show that if you use Lokelma or Patiromer to manage the potassium, these patients don't go to the emergency room nearly as often as those who are not on that treatment.
I've also want to remind people that these drugs, again, I've already said this, have been around for seven years and there's a huge experience in using them, both in primary and secondary care. Up to now, of course, primary care may not have felt that confident about commencing them. In North West London, we're going to try and produce some resources to support primary care clinicians, understand more clearly how to use these agents. We're going to produce what I hope will be a simple checklist. Which we'll put live on our website and of course when it's out there we probably ought to put it on our show notes that will help primary care just think what are the things you need to think about, what are the things you need to do. So Jeremy, let's take listeners through the contents of that checklist, starting with who is actually eligible to start the potassium binder.
Jeremy (07:39)
OK, so the following people are eligible for potassium binders. Lokelma is what we're talking about particularly, but it could be patiromer other than the potassium level. So patients have got to have chronic kidney disease with GFRs below 45 or to have heart failure.
They need a history of persistent hyperkalemia. So that's now a potassium of 5.5 or above for Lokelma but still six or above for patiromer which is also called Veltasaa. And critically, they need to be on submaximal doses of an ACE inhibitor, an angiotensin blocker, or one of the mineralocorticoid receptor antagonists, or even one of the ARBs, because of the hyperkalemia.
So this is about how we can maximise the doses of angiotensin blockade, where we know that that's beneficial. So chronic kidney disease or heart failure and not on maximum doses of angiotensin blockade with potassiums in the case of Lokelma of above 5.5. Not for patients on dialysis and not for women who are pregnant or planning a pregnancy and avoided in breastfeeding.
That's specifically for Patiromer
But the aim of the change isn't really about the potassium per se. It is about maximising angiotensin blockade, which will be beneficial for both heart failure and chronic kidney disease. And that will allow prevention of re-admission, reducing death rates, reducing morbidity and slowing progression of kidney disease.
Andrew
So Jeremy, you got really excited towards the end of that, and you're absolutely right to get excited and point out that the whole story of this podcast isn't about potassium management, it's about maximising RAASi Ace, Arb's, Arnes, MRA treatment to really protect kidneys and hearts.
Jeremy
Yeah, that's right. So that's what people need to remember from this. Before you actually write that first prescription or continue it, the patient should have had some advice about a low potassium diet. This is a group of patients whose potassium's are running high and so they should have advice about a low potassium diet. That doesn't mean no potassium because that isn't the major fact. It does mean they're avoiding potassium rich foods and lots of that's available out there and we can put a diet sheet on our show notes.
That issue that many of you will come across, pseudo hyperkalemia. That's where the potassium is high because of the way you've taken the blood or it's hanging around or some other reasons. That should be excluded. So you need to have had a recheck of the potassium. And if patients are on other potassium rising drugs, drugs causing hyperkalemia, and there are a few of them out there, drugs like cotrimoxazole, sometimes some of the acid suppressants and others, they should be stopped, but otherwise that's when you can start using the drug and you should have of course recent blood results for kidney function. And if you're using poterima, you ought to also know about their magnesium and their corrected calcium. It's not a big problem, but it is something to consider specifically for poterima.
Andrew
Okay Jeremy, so you've we've defined who. What about the starting dose? How do you kick it off?
Jeremy
and it's very straightforward for Lokelma, it's five grams once a day and for Poterima it's 8.4 grams once a day and they both come as sort of powders that the patient just dissolves in a fluid. So five grams for Lokelma, 8.4 grams for Viltassa.
Andrew
And as we've said, it's really about not just about the potassium, it's about getting maximisation of RAS. So what is really important is once you've done it, you then need to make the change to the RASI dose. And what we've done in our guidelines in North West London over the years is that once we have a patient established on the potassium binder within about a week, that's when you make the net the Increase in the RASI inhibitor dose or indeed if they're not on this, you start it. And you're aiming for a maximal dose of the RASI as long as the blood pressure is not too low. And then you need to recheck the bloods two weeks after commencing or increasing the RASI.
So the point is that if you just control the potassium and leave the ACE inhibitor, the ARB where it was, you've missed the whole point of starting the drug, and the patient actually doesn't get any benefit. You have to make that step. So we can push up these heart and kidney protecting medicines. And it's really important that the patient understands that's why you're using them. You're using the potassium binder to allow them to be on a medicine that is really going to reduce their risk of dialysis, reduce their risk of heart disease, and improve their cardiac function if they have heart failure. And they shouldn't stop the binder themselves without talking to you.
Jeremy
You're right Andrew, so that's been perfect how to start and how to use the drugs. We do need to say something about monitoring because that's concern in primary care and actually for these drugs it really shouldn't be a burden at all because it really is very straightforward. You've already described the beginning. You start the potassium binder, you've restarted or increased the dose of the angiotensin blockade, you check the potassium, two weeks later, which you would normally do because you've changed the dose or started or an angiotensin blockade. But thereafter, you only need to check the potassium every three to six months when you'd be checking kidney function. Now, if this patient's in a kidney clinic, we'd be doing that. But if they're in primary care, that's actually when you would normally be rechecking the kidney function. So there really are no extra checks needed at all. If patients are on poterima, then there is a need to check calcium and magnesium about a month after starting treatment and about every six months. But apart from the magnesium, the calcium would normally be checked as part of routine checking. And if they're in a kidney clinic, as I've said, they'd be having all that checked in that time window anyway.
Andrew
I pleased you really emphasise this because monitoring an extra workload is something that of course primary care are concerned about. And as you've described, once you've done that initial check, then the monitoring really falls in line with the underlying disorder that the patient has. So having given guidance on when to monitor, I suppose what we need to do is give some clear advice about how you react to that monitoring blood.
What do primary care do when two weeks after starting or increasing the RASSI and having been on the potassium binder they repeat the potassium, they find a potassium result, how do they respond to that.
Jeremy
Yes Andrew, so modifying the dose, should be very easy. If the potassium is less than 4, we need to reduce the dose. And that for most patients would mean moving to alternate day because they're only on 5 grams of Lokelma or 8.4 of Veltassa So lower than 4 millimoles per litre alternate day dosing. If it's between 4 and 5.2 millimoles per litre, then you just continue. You're in the perfect range. That's where you want potassium to be, between 4 and 5.2 mL per litre. And if the potassium is above 5.2, then you need to increase the dose of either the Lokelma or the Veltassa So if you were going to initially double it, that'd be 10 grams of Lokelma and 16.8 grams of Veltassa. And the maximum doses are actually 10 grams for Lokelma and 25.2 for Veltassa If you've increased the dose, recheck the potassium after four further weeks. But that's actually very unusual to be needed.
And for most people actually the initial doses, 5 grams and 8.4, are all that's needed. So what are we aiming for? Between 4 and 5.2 millimoles per litre of potassium is the perfect range.
Andrew
Excellent. Completely agree with you, Jeremy.
There are some minor issues I think you need to consider when you commence these agents and you need to ensure you've informed patients about these. The first relates to spacing the medicines from other medicines that they're taking. Of course, these patients will by they will or by necessity they will all be on additional medicines. And it's different for the Patiromer to Lokelma. So Patiromer ideally should not be administered within three hours. Of other medications. Lokemla can be administered with other medications, so it's easier to use in that situation. However, just a little thing that you need to be aware of, although this is not going to be a common situation, lokelma can transiently increase the gastric pH and should be administered separately, that's two hours before or two hours after, oral medicines which currently have a meaningful gastric pH dependent by availability. These are not commonly utilised drugs and include the azole antifungals, the anti-HIV drugs, tyrosine kinase inhibitors and certain immunosuppressants. So not common drugs. So it's worth though a quick check with the pharmacist or the product advice sheet if the patient is on a lot of other medications.
Jeremy
Yeah, that's right. And we've mentioned this already Andrew for Petiroma, they do need some calcium and magnesium monitoring, but no more frequently really than their disease. That's not needed with lokelma. So the other question I suppose GPs and primary care ask is when does the patient need to come back to us? A hospital clinic? Well, if the potassium stays above 5.5, despite, you know, being on a good dose of potassium binders, they've had some dietary advice, or if the potassium was to drop too low or if there was persistent side effects so you can't use them. So basically if you can't use these drugs for some reason and that would be an indication potentially for seeking further advice. But those are actually pretty uncommon. The more important issue is if the potassium is so uncontrolled that it remains high and our audience can go back and listen to our episode about when potassium is really high. But to remind everybody we're really only very worried for urgent emergency care if the potassium is above 6.5 millimoles per litre or if they were significantly worsening heart failure, for example, or an acute illness. But that's when we want to see people again.
Andrew
Do want to say something, Jeremy, about so oral sodium bicarbonate? 'Cause I recall that you've got strong views on this, which I probably agree with.
Jeremy
yeah, it just doesn't work. So what we're talking about is managing hyperkalemia, high potassium. Quite often doctors throw some oral sodium bicarbonate thinking it will lower it. It doesn't. Taking oral bicarbonate really doesn't lower your potassium to any significant amount at all. It is advantageous in the setting of severe hyperkalemia and trying to prevent acute arrhythmias. But adding sodium bicarbonate, we do use it if people are acidotic. But it is not a preventative treatment for hyperkalemia. And everybody seems to forget this Andrew, not just primary care, but all of our renal registrars as well. So we do use bicarbonate for acute hyperkalemia as an arrhythmia preventing device, but please, and if somebody's added it in the hospital, they probably didn't need it unless it was for treating acidosis itself, not the potassium. And it always causes side effects.
Andrew
I completely agree. Unfortunately it's in a lot of the guidelines as well and so patients do often go through that stage. But I completely agree with you on that. So Jeremy, let's bring this together and let's hear your top three take home messages.
Jeremy
It's me this week, isn't it? Okay, so firstly, take a proactive approach to maximising inhibition of the Renin-Angiotensin system in patients with chronic kidney disease. And you can now do that even if they've got chronic hyperkalemia. That's what we're driving for. What's changed has been starting low-kelma. The threshold has dropped to a potassium of 5.5 when patients cannot take maximum doses of ACES or ARBs. That's what's new. That's what's exciting. But about increasing the ACE or ARB dosing when you can't because of potassium. And the third point is once starting Lokelma or Poterima and the potassium drops, don't forget to increase the ACE or ARB dose. Don't stop the potassium binder, increase the ACE or the ARB. That's what you're trying to do.
Andrew
That's exactly it. And we'll try and get the checklist when we finalise it into the show notes and also the potassium dietary advice, although I suspect we've got them in our previous show notes.
Jeremy
And they're available everywhere for thinking about potassium diets. great, great conversation, Andrew. Thank you, everyone, for listening. And if you have other ideas for topics that you want us to talk about, then get in touch.
Andrew
So thank you very much, Jeremy. Bye for now.